However, the largest Phase IIb trial involving 536 subjects failed to demonstrate statistically significant weight loss compared to placebo at the primary 12-week endpoint, leading Metabolic Pharmaceuticals to terminate development in 2007
The results of once daily administration of the peptide for 12 weeks showed that the drug tripled weight loss when compared to placebo and that the rate of weight loss remained steady during the trial period
Research indicates that it works by: Increasing blood vessel formation (angiogenesis) to enhance nutrient delivery to injured areas
BPC-157 has been studied extensively for gastrointestinal protection, including reducing damage from NSAIDs and promoting gastric lining repair
Staying informed through credible resources is essential
He always returned, and after slobbering all over me, saying what a good boy I was, how I was his favorite and someday I would be a great boxer, he would then stagger out for the night and not return until the bars were closing
